A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations.

Cancer Med · 2023 · PMC10469738 · PMID 37403699

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although no statistical difference was concluded, NRAS‐mutant patients treated with anti‐PD‐1 antibodies even showed a trend toward poorer survival compared to IFN treatment or observation.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.